Home / Featured

Immunotherapy Response Biomarkers

Predicting who benefits from checkpoint blockade: the tumour immune microenvironment, quantitative mismatch-repair and microsatellite measures, and the co-medications that blunt a response before it starts.

6 articles in this topic

  • November 16, 2026Clinical Cancer ResearchSingle-arm phase II (NCT05383716)

    Neoadjuvant Pembrolizumab Plus Chemotherapy Yields 37.5% Major Pathologic Response in Resectable NSCLC; Exploratory Spatial Profiling Separates Myeloid- and Lymphoid-Enriched Responders in a Single-Arm Phase II Trial

    In a single-center, single-arm phase II trial of neoadjuvant pembrolizumab plus platinum-based chemotherapy in 80 patients with resectable stage IIA–IIIB (N2) NSCLC, major pathologic response (MPR) occurred in 30 (37.5%) and pathologic complete response (pCR) in 21 (26.3%). Median event-free survival (EFS) was not reached (95% CI, 42.1–NR) and 24-month EFS was 71.9% (95% CI, 62.6–82.6). Grade 3 or 4 treatment-related adverse events occurred in 21 (26.3%), and one patient died of immune-related myocarditis.

  • November 16, 2026Clinical Cancer ResearchRetrospective single-center cohort, Dana-Farber Cancer Institute (no ClinicalTrials.gov registration)

    MTAP-Deleted Advanced NSCLC Is Linked to Shorter PFS on Immunotherapy-Based Regimens, With No Significant Overall Survival Difference, in a Retrospective Single-Center Cohort

    In a retrospective single-center cohort of 400 patients with advanced NSCLC (93 MTAP-deleted, 307 MTAP wild-type), MTAP deletion was associated with shorter progression-free survival on anti-PD-(L)1 monotherapy (median 2.0 vs 4.9 months; multivariable HR 1.70, 95% CI 1.02–2.82; p=0.040) and on platinum doublet plus anti-PD-(L)1 (median 4.2 vs 7.5 months; multivariable HR 1.89, 95% CI 1.20–2.97; p=0.006).

  • October 1, 2026Clinical Cancer ResearchA-BRAVE (phase III, NCT02926196)

    High Baseline TILs Flag Adjuvant Avelumab Benefit in High-Risk Triple-Negative Breast Cancer, but the A-BRAVE Trial Missed Its Co-Primary Endpoints and the Finding Is Hypothesis Generating

    A-BRAVE randomized 466 patients with high-risk early triple-negative breast cancer (TNBC) to 52 weeks of adjuvant avelumab or observation. The co-primary endpoints were not met (ITT DFS: HR 0.81; 95% CI 0.61–1.09; P = 0.172). This report is a prespecified analysis of the prognostic and predictive role of stromal tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB).

  • August 19, 2026Clinical Cancer ResearchHCRN GU16-260 (NCT03117309)

    Tumor Immune Cell Biomarkers Predict Response to First-Line Nivolumab in Kidney Cancer

    In a correlative biomarker analysis of the HCRN GU16-260 trial, non-exhausted CD8+ T cells were linked to higher response rates and longer progression-free survival in treatment-naive metastatic clear-cell RCC treated with first-line nivolumab.

  • August 7, 2026The Lancet OncologyPACIFIC post-hoc analysis (NCT02125461)

    PPIs and Antibiotics Linked to Blunted Durvalumab Benefit in Stage III NSCLC

    A post-hoc analysis of the phase III PACIFIC trial (660 of 713 originally randomized patients; 449 durvalumab, 211 placebo) examined whether baseline exposure to proton pump inhibitors (PPIs) or antibiotics was associated with worse outcomes after consolidation durvalumab for unresectable stage III NSCLC, at a median follow-up of 62.4 months.

  • July 23, 2026Clinical Cancer Research

    Quantitative MSI Burden Predicts Immunotherapy Response and Survival in dMMR Colorectal Cancer

    Retrospective, single-center biomarker cohort study of 39 patients with dMMR metastatic colorectal cancer treated with anti-PD-1 monotherapy at Mayo Clinic, using integrated exome, transcriptome, and immune-repertoire profiling to test whether quantitative MSI burden — not just binary MSI-high status — predicts benefit from checkpoint blockade

Cancer types covered: Lung Cancer · Breast Cancer · Kidney Cancer · Colorectal Cancer